证券代码：600789 证券简称：鲁抗医药 公告编号：2023-021 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2022 年度及 2023 年第 一季度的经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息 披露允许的范围内就投资者普遍关注的问题进行回答。 山东鲁抗医药股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 05 月 11 日(星期四)至 05 月 17 日(星期三)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 lkpc_dmc@126.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行 回答。 山东鲁抗医药股份有限公司（以下简称"公司"）已于 2023 年 4 月 19 日发 布公司 2022 年度报告和 2023 年第 ...

Financial Performance - In 2022, the company achieved a consolidated net profit attributable to shareholders of the parent company of CNY 138,013,129.39, representing a 54.90% increase compared to the previous year[6]. - The operating revenue for 2022 was CNY 5,621,441,903.66, which is a 14.17% increase from CNY 4,923,783,870.87 in 2021[22]. - The net cash flow from operating activities reached CNY 444,377,008.97, marking a significant increase of 150.36% compared to CNY 177,492,024.62 in the previous year[22]. - The total assets of the company at the end of 2022 were CNY 8,727,665,447.53, an increase of 11.57% from CNY 7,822,429,397.11 at the end of 2021[23]. - The net assets attributable to shareholders of the parent company were CNY 3,356,856,234.48, reflecting a 2.25% increase from CNY 3,282,963,859.81 in 2021[23]. - Basic earnings per share increased by 60% to CNY 0.16 in 2022 from CNY 0.10 in 2021[24]. - The company reported a net profit excluding non-recurring gains and losses of CNY 86,962,978.51, which is a 141.76% increase from CNY 35,971,269.00 in the previous year[22]. - The gross profit from the main business reached 1.22 billion RMB, an increase of 5.68% compared to the previous year[50]. - The total revenue for 2022 was approximately CNY 5.54 billion, with a gross profit margin of 22.01%, reflecting a year-over-year decrease of 1.67 percentage points[59]. Strategic Developments - The company plans to distribute a cash dividend of CNY 0.55 per 10 shares (including tax) to all shareholders[6]. - The company’s future plans and strategic developments are subject to investment risks and do not constitute a commitment to investors[7]. - The company plans to continue expanding its product pipeline and enhancing marketing capabilities to drive future growth[59]. - The company aims to maintain and improve market share in niche products through flexible sales strategies and optimized business lines[86]. - The company will actively conduct industry policy research to align with policy directions and enhance brand building[86]. - The company is committed to promoting transformation and upgrading through consistent evaluation and new product development[87]. - The company plans to enhance research and development efforts, focusing on anti-infection products and expanding its product pipeline across multiple therapeutic areas[87]. Research and Development - R&D investment for 2022 was CNY 311 million, with significant progress in the pipeline for anti-infection and cardiovascular drugs[35]. - The company holds 47 new patent authorizations in 2022, enhancing its technological and innovation capabilities[51]. - The company has developed a complete product chain from fermentation raw materials to semi-synthetic raw materials and formulations, covering over 500 specifications[44]. - The company is focusing on innovative drugs and generic drug applications, biotechnology product development, and product transformation to enhance its product portfolio[106]. - The total R&D investment for the reporting period was CNY 311 million, accounting for 5.52% of total operating revenue, which is relatively high compared to industry peers[106]. - The company is actively expanding its product types and strengthening its product chain through scientific research and development efforts[106]. Market Performance - Revenue from formulation products reached CNY 1.902 billion in 2022, with new product sales contributing over CNY 70 million[33]. - The revenue from the antibiotic segment was CNY 255.82 million, with a gross profit margin of 18.53%, showing a year-over-year decrease of 10.46%[59]. - The revenue from veterinary antibiotics increased significantly, reaching CNY 2.31 billion, with a gross profit margin of 15.66%, marking a year-over-year increase of 43.04%[59]. - The domestic revenue accounted for CNY 4.78 billion, with a gross profit margin of 23.96%, reflecting a year-over-year increase of 16.09%[59]. - The company is recognized as one of the four major antibiotic production bases in China, with a strong market presence in penicillin and cephalosporin products[52]. Operational Efficiency - The company achieved a cost reduction of CNY 78.7827 million through efficiency improvements and production optimization[34]. - The company invested CNY 157 million in production automation, establishing 12 post-packaging production lines and deploying 14 robots, resulting in a 45.77% increase in labor productivity[37]. - The company’s automation and information technology initiatives have been recognized as a national pilot demonstration project by the Ministry of Industry and Information Technology[36]. - The company has implemented a dynamic management system for suppliers, ensuring quality and reducing procurement costs[45]. Environmental Responsibility - The company’s environmental investment in 2022 was CNY 173.39 million, with successful completion of pollution control assessments for three subsidiaries[38]. - The company is committed to enhancing its environmental and safety standards in response to increasing regulatory pressures, aiming for compliance with national carbon neutrality goals[135]. - The company has established a governance structure to protect the interests of shareholders, particularly minority shareholders, ensuring transparent information disclosure[191]. - The company was recognized as a national-level "Green Factory," reflecting its commitment to environmental responsibility and sustainable practices[188]. Governance and Compliance - The company held two shareholder meetings during the reporting period, ensuring compliance with legal requirements and facilitating shareholder participation[138]. - The board of directors operates under strict regulations, with established committees to enhance decision-making and oversight functions[139]. - The company adheres to strict information disclosure regulations, preventing selective disclosure and insider trading[141]. - The company has a comprehensive risk management report that was approved in the last board meeting of the year[156]. Future Outlook - The company aims for a revenue target of 6 billion yuan in 2023, representing a year-on-year growth of over 7%[124]. - Financial guidance for the upcoming fiscal year suggests a projected revenue growth of approximately 15%[148]. - The company plans to enhance the profitability and competitiveness of its raw materials through the "Peak Plan" and aims to optimize technology and quality while reducing costs[125]. - The company is positioned to benefit from the stable implementation of volume-based procurement policies, seeking innovation and channel expansion to enhance profitability[121].

Financial Performance - The company's operating revenue for Q1 2023 was CNY 1,669,812,908.04, representing a year-on-year increase of 25.42% compared to CNY 1,324,581,073.87 in the same period last year[3]. - The net profit attributable to shareholders of the listed company was CNY 45,688,589.04, a slight increase of 1.59% from CNY 44,588,853.42 in the previous year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses surged by 77.02% to CNY 41,375,154.29 from CNY 23,629,646.82 in the same period last year[3]. - The company reported a basic earnings per share of CNY 0.05, unchanged from the previous year[4]. - The total comprehensive income for the first quarter of 2023 was CNY 47,414,780.36, an increase from CNY 46,090,528.29 in the same period of 2022, representing a growth of approximately 2.86%[16]. Cash Flow - The net cash flow from operating activities increased by 92.05% to CNY 130,889,329.27, compared to CNY 68,459,009.16 in the previous year[4]. - The net cash flow from operating activities for Q1 2023 was CNY 130,889,329.27, significantly higher than CNY 68,153,420.75 in Q1 2022, indicating an increase of about 92.4%[18]. - The total cash inflow from financing activities was CNY 697,270,082.10 in Q1 2023, compared to CNY 228,329,538.31 in Q1 2022, reflecting a substantial increase of approximately 205.5%[19]. - The net cash flow from financing activities for Q1 2023 was -CNY 137,996,819.86, worsening from -CNY 9,018,694.18 in Q1 2022[19]. - The cash and cash equivalents at the end of Q1 2023 stood at CNY 323,314,673.48, down from CNY 395,130,807.40 at the end of Q1 2022, a decrease of about 18.2%[19]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 8,548,945,159.23, a decrease of 2.50% from CNY 8,727,665,447.53 at the end of the previous year[4]. - Current liabilities decreased to ¥3,526,689,113.33 from ¥4,129,057,002.94, representing a reduction of 14.6%[12]. - The total liabilities decreased to ¥4,979,764,208.53 from ¥5,220,496,898.35, a decline of 4.6%[13]. - Long-term borrowings increased to ¥1,236,885,323.06 from ¥867,176,000.00, indicating a rise of 42.5%[12]. Shareholder Information - The company has 116,523 common shareholders as of the end of the reporting period[8]. - The top shareholder, Hualu Holdings Group Co., Ltd., holds 20.91% of the shares, totaling 185,896,620 shares[8]. Research and Development - Research and development expenses increased to ¥72,066,772.99 in Q1 2023, compared to ¥60,176,722.79 in Q1 2022, marking a rise of 19.7%[15]. Inventory and Expenses - Inventory as of March 31, 2023, was ¥1,503,632,882.92, slightly up from ¥1,480,685,151.67 at the end of 2022[12]. - The cash paid for purchasing goods and services in Q1 2023 was CNY 635,306,475.83, down from CNY 741,247,430.29 in Q1 2022, representing a decrease of about 14.3%[18]. - The company received CNY 18,184,609.68 in tax refunds during Q1 2023, compared to CNY 23,881,168.78 in Q1 2022, a decline of approximately 23.9%[18]. - The company incurred cash outflows of CNY 73,776,345.22 for taxes in Q1 2023, which is significantly higher than CNY 27,151,145.58 in Q1 2022, an increase of about 171.5%[18]. Acquisition - The company acquired a 60% stake in Shandong Rukang Zhonghe Environmental Technology Co., Ltd. for CNY 62.0659 million, which was completed on August 24, 2022, and is now a wholly-owned subsidiary[4].

Group 1: Event Details - The event is organized by Shandong Securities Regulatory Bureau and Shandong Listed Companies Association [1] - The online event will take place on November 16, 2022, from 14:00 to 16:00 [1] - Investors can participate via the "Investor Relations Interactive Platform" provided by P5W [1] Group 2: Company Representatives - The company's Chairman, Mr. Peng Xin, will be present for the online communication [1] - The Chief Financial Officer, Mr. Li Li, will also participate in the event [1] - Other representatives include Board Secretary Mr. Tian Lixin and Securities Affairs Representative Mr. Bao Qiangming [1] Group 3: Discussion Topics - Topics for discussion include corporate governance and social responsibility/ESG [1] - The company's operational status and development strategy will be addressed [1] - Risk prevention and investor protection, along with the third-quarter report, will be key points of interest [1]

2022 年第三季度报告 单位：元 币种：人民币 证券代码：600789 证券简称：鲁抗医药 山东鲁抗医药股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 本报告期 年初至报告期 | --- | --- | --- | --- | --- | |------------------------------------------------|------------------|------------------------------|------------------|---------------------------- ...

2022 年半年度报告 公司代码：600789 公司简称：鲁抗医药 山东鲁抗医药股份有限公司 2022 年半年度报告 1 / 149 2022 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人彭欣、主管会计工作负责人李利及会计机构负责人（会计主管人员）荣姝伟声明： 保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中涉及的未来计划、发展战略等前瞻性描述，不构成公司对投资者的实质承诺，敬请 投资者注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、 重大风险提示 报告期内，不存在对公司生产经营产生实质性影响的特别 ...

2022 年第一季度报告 单位：元 币种：人民币 证券代码：600789 证券简称：鲁抗医药 山东鲁抗医药股份有限公司 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务报表 信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | |-----------------------------------------------|------------------|---------------------------------------| | 项目 | 本报告期 | 本报告期比上年同期增减 \n变动幅度 (%) | | 营业收入 | 1,324,581, ...

2021 年年度报告 公司代码：600789 公司简称：鲁抗医药 山东鲁抗医药股份有限公司 2021 年年度报告 1 / 191 2021 年年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 上会会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、 公司负责人彭欣、主管会计工作负责人李利及会计机构负责人（会计主管人员）荣姝伟声明： 保证年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 经上会会计师事务所（特殊普通合伙）审计，公司 2021 年度实现合并归属于母公司所有者 的净利润 82,685,648.18 元，截止报告期末，母公司可供股东分配利润余额 76,277,139.78 元。 公司拟以实施利润分配方案时股权登记日登记的总股本为基数，向全体股东每 10 股派发现金红利 0.5 元（含税）。 以上预案尚需股东大会审议通过。 六、 前瞻性陈述的风险声明 √适 ...

证券代码：600789 证券简称：鲁抗医药 公告编号：2021—049 山东鲁抗医药股份有限公司 关于参加山东辖区上市公司2021年度投资者 网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 为进一步加强与广大投资者的沟通交流，山东鲁抗医药股份有限公司（以下 简称"公司"）将参加由山东证监局、山东上市公司协会联合举办并由深圳市全 景网络有限公司承办的"山东辖区上市公司 2021 年度投资者网上集体接待日活 动"，现将有关事项公告如下： 本次集体接待日活动将采取网络远程的方式举行，投资者可以登录"全景 • 路演天下"网站（http://rs.p5w.net）参与本次活动。活动时间为 2021 年 11 月 16 日（星期二）14:00 至 16:00。 届时公司财务总监李利先生、董事会秘书田立新先生、证券事务代表包强明 先生将通过网络在线交流形式与投资者就本公司治理及社会责任/ESG、经营状 况、发展战略、风险防控、投资者保护、三季度报告等投资者关注的问题进行沟 通，欢迎广大投资者积极参与。 特此公 ...

2021 年第三季度报告 单位：元 币种：人民币 证券代码：600789 证券简称：鲁抗医药 山东鲁抗医药股份有限公司 2021 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 报表信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 本报告期 年初至报告期 | --- | --- | --- | --- | --- | |------------------------------------------------|------------------|------------------------------|------------------|----------------------- ...